Cas:1013-88-3 Benzophenoneimine manufacturer & supplier

Chemical Name:Benzophenoneimine

CAS.NO:1013-88-3

Synonyms:BENZHYDRYLIDENEAMINE;benzophenone-imine;Benzophone imine;Benzophenone imine;Benzhydrylidenimine;Diphenylketimine;1,1-Diphenylmethanimine;BENZOPHENONIMINE;Benzenemethanimine, α-phenyl-;Benzophenoneimine;N-(diphenylmethylene)amine;Benzophenone lmine;Benzhydrylimine;Diphenylmethanimineimine;diphenylmethanimine;MFCD00001760

Molecular Formula:C₁₃H₁₁N

Molecular Weight:181.233

HS Code:2933399090

Physical and Chemical Properties:

Melting point:-30 °C

Boiling point:282.0±9.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.567

PSA:23.85000

Exact Mass:181.089142

LogP:2.65

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like BENZHYDRYLIDENEAMINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00001760 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzophenoneimine Use and application,Benzophenone lmine technical grade,usp/ep/jp grade.

Related News: The researchers also found that Black women are much less likely to undergo genetic counseling and testing, largely due to differences in physician recommendations or access to care. Benzophenoneimine manufacturer However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. Benzophenoneimine supplier Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. Benzophenoneimine vendor Roche too has been riding high on the stock exchange this week, as investors still hope its more extensive Alzheimer’s profile could come good. Benzophenoneimine factory The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.